ASND Stock Recent News

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.

On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel Yun Zhong - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call.

– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares

– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million

• Funds to Progress Lagoa Salgada Project and extinguish a significant portion of short-term payables • Additional Support Received for Arrangement with Cerrado NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / February 11, 2025 / Ascendant Resources Inc. (TSX:ASND) ("Ascendant" or the "Company") is pleased to announce closing of the first tranche ("First Tranche(TSX:ASND) ("Ascendant" or the "Company") is pleased to announce closing of the first tranche ("First Tranche") of the private placement (the "Placement") previously announced on February 3, 2025 in connection with the arrangement agreement (the "Arrangement Agreement") it entered into with Cerrado Gold Inc. ("Cerrado"), whereby Cerrado has agreed to acquire all of the issued and outstanding common shares of Ascendant (each an "Ascendant Share") by way of a plan of arrangement (the "Arrangement"). Under the First Tranche, the Company has issued 45,047,6

COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results.

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenue of $62.4M; validates TransCon platform technology. Novo deal for monthly GLP-1 in obesity could be game-changing; includes $285M in milestones plus royalties and expansion options.

Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth potential. Ascendis' diverse pipeline supports a positive investment thesis, suggesting significant future advancements and market opportunities.

- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P.